Bio-Rad Laboratories, Inc. Class B (NYSE:BIO.B)
June 14th, 2019
Bio-Rad Laboratories, Inc. Class B neither rose nor fell during ‘s trading, but stayed put at $291.07.
BIO.B outperformed the rest of the Healthcare sector which went down -0.29% today.
Forecasts from 1 analyst suggest that Bio-Rad Laboratories, Inc. Class B might increase significantly (20.25%), while Finbox has calculated (with low uncertainty) a fair value price of $338.71.
The market sectors were mixed Friday with a majority of the sectors trending up. Utilities saw the biggest increase of the day (0.99%), while the Information Technology sector saw the biggest drop (-0.83%). Information Technology has seen the biggest year-to-date gain of 23.33%.
Utilities saw the biggest turn-around compared to its 5-day performance (-0.59%), as it went up by 0.99%. Information Technology and Energy experienced turn-arounds from their five day positive performances with Information Technology dropping -0.83%.
- Utilities, up 0.99%.
- Communication Services, up 0.39%.
- Real Estate, up 0.33%.
- Financials, up 0.26%.
- Consumer Discretionary, up 0.24%.
- Consumer Staples, up 0.03%.
- Healthcare, down -0.29%.
- Industrials, down -0.39%.
- Materials, down -0.47%.
- Energy, down -0.74%.
- Information Technology, down -0.83%.
Bio-Rad Laboratories, Inc. Class B Info
Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
All amounts in USD unless otherwise indicated
Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.